GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » Piotroski F-Score

ORGO (Organogenesis Holdings) Piotroski F-Score : 7 (As of Jul. 24, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Organogenesis Holdings has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Organogenesis Holdings's Piotroski F-Score or its related term are showing as below:

ORGO' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 8
Current: 7

During the past 10 years, the highest Piotroski F-Score of Organogenesis Holdings was 8. The lowest was 1. And the median was 5.


Organogenesis Holdings Piotroski F-Score Historical Data

The historical data trend for Organogenesis Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organogenesis Holdings Piotroski F-Score Chart

Organogenesis Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 6.00 7.00 4.00 8.00

Organogenesis Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 5.00 8.00 7.00

Competitive Comparison of Organogenesis Holdings's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was -17.043 + 12.331 + 7.673 + -18.843 = $-15.9 Mil.
Cash Flow from Operations was 4.738 + 8.695 + 10.937 + -19.935 = $4.4 Mil.
Revenue was 130.234 + 115.177 + 126.656 + 86.693 = $458.8 Mil.
Gross Profit was 101.036 + 88.381 + 95.605 + 62.97 = $348.0 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was
(458.481 + 443.163 + 446.296 + 497.886 + 467.394) / 5 = $462.644 Mil.
Total Assets at the begining of this year (Mar24) was $458.5 Mil.
Long-Term Debt & Capital Lease Obligation was $33.4 Mil.
Total Current Assets was $268.2 Mil.
Total Current Liabilities was $65.1 Mil.
Net Income was 5.316 + 3.167 + -0.568 + -2.1 = $5.8 Mil.

Revenue was 117.316 + 108.531 + 99.651 + 109.976 = $435.5 Mil.
Gross Profit was 91 + 82.742 + 71.882 + 81.28 = $326.9 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was
(446.107 + 450.313 + 462.647 + 460.025 + 458.481) / 5 = $455.5146 Mil.
Total Assets at the begining of last year (Mar23) was $446.1 Mil.
Long-Term Debt & Capital Lease Obligation was $96.4 Mil.
Total Current Assets was $227.2 Mil.
Total Current Liabilities was $82.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Organogenesis Holdings's current Net Income (TTM) was -15.9. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Organogenesis Holdings's current Cash Flow from Operations (TTM) was 4.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=-15.882/458.481
=-0.03464048

ROA (Last Year)=Net Income/Total Assets (Mar23)
=5.815/446.107
=0.01303499

Organogenesis Holdings's return on assets of this year was -0.03464048. Organogenesis Holdings's return on assets of last year was 0.01303499. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Organogenesis Holdings's current Net Income (TTM) was -15.9. Organogenesis Holdings's current Cash Flow from Operations (TTM) was 4.4. ==> 4.4 > -15.9 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=33.375/462.644
=0.0721397

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=96.41/455.5146
=0.21165074

Organogenesis Holdings's gearing of this year was 0.0721397. Organogenesis Holdings's gearing of last year was 0.21165074. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=268.16/65.053
=4.1221773

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=227.167/82.799
=2.74359594

Organogenesis Holdings's current ratio of this year was 4.1221773. Organogenesis Holdings's current ratio of last year was 2.74359594. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Organogenesis Holdings's number of shares in issue this year was 126.296. Organogenesis Holdings's number of shares in issue last year was 131.862. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=347.992/458.76
=0.75854913

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=326.904/435.474
=0.75068546

Organogenesis Holdings's gross margin of this year was 0.75854913. Organogenesis Holdings's gross margin of last year was 0.75068546. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=458.76/458.481
=1.00060853

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=435.474/446.107
=0.97616491

Organogenesis Holdings's asset turnover of this year was 1.00060853. Organogenesis Holdings's asset turnover of last year was 0.97616491. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+1+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Organogenesis Holdings has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Organogenesis Holdings  (NAS:ORGO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Organogenesis Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Organogenesis Holdings Business Description

Traded in Other Exchanges
Address
85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Executives
Michael Joseph Driscoll director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney director, officer: President and CEO C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Albert Erani 10 percent owner 150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz 10 percent owner
Arthur S Leibowitz director 139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Gilberto Quintero director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin director 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo officer: VP Health Policy & Contracting C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin director 7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu director C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf director, 10 percent owner
Alan A. Ades director, 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021